CA2239868A1 - Compositions et procede servant a stimuler la liberation d'anticorps par les lymphocytes b - Google Patents
Compositions et procede servant a stimuler la liberation d'anticorps par les lymphocytes b Download PDFInfo
- Publication number
- CA2239868A1 CA2239868A1 CA002239868A CA2239868A CA2239868A1 CA 2239868 A1 CA2239868 A1 CA 2239868A1 CA 002239868 A CA002239868 A CA 002239868A CA 2239868 A CA2239868 A CA 2239868A CA 2239868 A1 CA2239868 A1 CA 2239868A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- csf
- antibody
- cell
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55533—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
L'invention concerne des compositions comprenant le facteur de stimulation de populations de macrophages granulocytes (GM-CSF), interleukine-3 (IL-3) ou leur combinaison servant à stimuler la libération d'anticorps par les lymphocytes B. Elle concerne également des procédés d'utilisation de ces compositions, des compositions pharmaceutiques, des vaccins, ainsi que des adjuvants de vaccins. Elle concerne, de plus, une technique permettant d'identifier des composés capables de stimuler la libération d'anticorps par les lymphocytes B.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56834395A | 1995-12-06 | 1995-12-06 | |
US08/568,343 | 1995-12-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2239868A1 true CA2239868A1 (fr) | 1997-06-12 |
Family
ID=24270896
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002239868A Abandoned CA2239868A1 (fr) | 1995-12-06 | 1996-12-05 | Compositions et procede servant a stimuler la liberation d'anticorps par les lymphocytes b |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0866871A1 (fr) |
JP (1) | JP2000502995A (fr) |
AU (1) | AU1146597A (fr) |
CA (1) | CA2239868A1 (fr) |
WO (1) | WO1997020940A1 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9909077D0 (en) * | 1999-04-20 | 1999-06-16 | Smithkline Beecham Biolog | Novel compositions |
CA2522002A1 (fr) | 2003-04-11 | 2004-11-18 | Dewhurst Solution, Llc | Tete de club de golf comportant un systeme de transfert de forces |
CA2959477C (fr) | 2014-06-11 | 2020-10-20 | Riken | Peptide antigenique de meme type multiplexe |
US9815886B2 (en) | 2014-10-28 | 2017-11-14 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
CN108567977B (zh) * | 2017-03-13 | 2022-04-12 | 复旦大学 | 一种免疫增强剂、免疫治疗药物组合物及其制备与用途 |
US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09507055A (ja) * | 1993-11-10 | 1997-07-15 | ヘンリー エム.ジャクソン ファウンデーション フォー ザ アドバンスメント オブ ミリタリー メディスン | Bリンパ球による抗体放出を刺激するための組成物および方法 |
-
1996
- 1996-12-05 AU AU11465/97A patent/AU1146597A/en not_active Abandoned
- 1996-12-05 CA CA002239868A patent/CA2239868A1/fr not_active Abandoned
- 1996-12-05 JP JP9521404A patent/JP2000502995A/ja active Pending
- 1996-12-05 EP EP96942887A patent/EP0866871A1/fr not_active Withdrawn
- 1996-12-05 WO PCT/US1996/019327 patent/WO1997020940A1/fr not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2000502995A (ja) | 2000-03-14 |
EP0866871A1 (fr) | 1998-09-30 |
AU1146597A (en) | 1997-06-27 |
WO1997020940A1 (fr) | 1997-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chen et al. | Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocyte-macrophage colony-stimulating factor. | |
KR102609197B1 (ko) | 인터류킨 15 단백질 복합체 및 그의 용도 | |
AU779388B2 (en) | Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens | |
AU2007271398B2 (en) | Compositions and methods for enhancing the efficacy of IL-2 mediated immune responses | |
KR20210038549A (ko) | Il2 작용제 | |
CA3082904A1 (fr) | Agonistes partiels de l'interleukine-2 | |
AU2003228362A1 (en) | Antibody fusion proteins: effective adjuvants of protein vaccination | |
CZ289099B6 (cs) | Imunokonjugát, způsob jeho výroby a pouľití a farmaceutický přípravek na jeho bázi | |
JP2008500812A (ja) | 免疫抑制サイトカイン | |
US10077296B2 (en) | Methods and compositions for the treatment and prevention of cancer | |
KR100559918B1 (ko) | 강화 백신 | |
AU5170796A (en) | Compositions and methods for stimulating antibody class switching | |
DE60128070T2 (de) | Impfstoff spezifisch gegen nierentumore, gerichtet gegen das antigen g-250 des nierentumors | |
Snapper et al. | IFN-γis a potent inducer of Ig secretion by sort-purified murine B cella activated through the mlg, but not the CD40, signaling pathway | |
US5932427A (en) | In vitro assay system for identifying compositions useful for stimulating B cells | |
CA2239868A1 (fr) | Compositions et procede servant a stimuler la liberation d'anticorps par les lymphocytes b | |
Boraschi et al. | Interleukin-1 and interleukin-1 fragments as vaccine adjuvants | |
AU716806B2 (en) | Induction and enhancement of the immune response to polysaccharides with bacterial lipoproteins | |
WO1996032963A9 (fr) | Declenchement et renforcement de la reaction immunitaire aux polysaccharides a l'aide de lipoproteines bacteriennes | |
CA3133414A1 (fr) | Variants du recepteur de l'interleukine-2 (il2r) et de l'interleukine-2 (il2) pour l'activation specifique de cellules effectrices immunitaires | |
Cruz | Anti-HER2/neu IgG3-(IL-2) and anti-HER2/neu IgG3-(GM-CSF) antibody fusion proteins are potent adjuvants of HER2/neu vaccination: Characterization of a HER2/neu specific anti-tumor immune response and immune activation | |
Roberts | Vaccination against normal and neoplastic B cells with CD20 peptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |